Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04706923 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection
A Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections, sponsored by SymBio Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 11
- Study locations
NCT04706923: Recruiting Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections, sponsored by SymBio Pharmaceuticals.
NCT04706923 is a Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections that is actively recruiting participants, run by SymBio Pharmaceuticals. The registered enrollment target is 52 participants, below the 234-participant average among 5 other Cytomegalovirus Infection trials with a reported enrollment target (78% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04706923, a Phase 2 study of Cytomegalovirus Infection and Adenovirus Infections, is actively recruiting participants, sponsored by SymBio Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
Primary Outcome
Safety will be evaluated based on incidence and severity of Adverse Events, Serious Adverse Events and laboratory assessments.
Conditions Studied
Interventions
- DRUG BCV
Study Locations (11)
California
- Research Site - Los Angeles
- Research Site - Los Angeles
- Research Site - San Francisco
Illinois
- Research Site - Chicago
Nebraska
- University of Nebraska Medical Center - Omaha
North Carolina
- Research Site - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Research Site - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - Memphis
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 2 |
What NCT04706923 shows while recruiting
NCT04706923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 234-participant average among 5 other Cytomegalovirus Infection trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Cytomegalovirus Infection appearing as the primary indexed condition, and to 1 intervention - of which BCV is the first listed.
NCT04706923 lists 11 locations in 9 states (California, Illinois, Nebraska).
Frequently Asked Questions
What is clinical trial NCT04706923 about?
NCT04706923 is a clinical study titled "A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection". The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
What is the current status of trial NCT04706923?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-08-16. Estimated completion is 2026-09-30.
What conditions does trial NCT04706923 study?
This clinical trial studies the following conditions: Cytomegalovirus Infection, Adenovirus Infections.
What interventions are being tested in trial NCT04706923?
The interventions under investigation include: BCV (DRUG).
Who is sponsoring clinical trial NCT04706923?
This trial is sponsored by SymBio Pharmaceuticals, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04706923 being conducted?
This trial has 11 study locations across California, Illinois, Nebraska, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cytomegalovirus Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.
RECRUITING · Phase 2
-
Dried Blood Spot Testing of CMV Detection in HCT Recipients
COMPLETED · NA
-
Cytomegalovirus (CMV) Infection in Pregnancy
COMPLETED
-
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
COMPLETED · Phase 1
-
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI